Could a shorter treatment be just as good for AML in the elderly?
NCT ID NCT07407660
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a shorter course of the drug venetoclax (combined with azacitidine) works as well as the standard longer course for older or frail patients with acute myeloid leukemia (AML). The researchers will check bone marrow on day 14 to decide if the drug can be stopped early. The trial plans to enroll 250 participants and compare how many achieve remission within two cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax and azacitidine
What this could lead to
If successful, this could lead to a shorter, less toxic treatment option for elderly or frail patients with acute myeloid leukemia, potentially reducing side effects while maintaining effectiveness.
What could go wrong
This is a phase 3 trial, but it has not yet started recruiting. The shortened course may not be as effective as the standard regimen, and there is a risk of disease progression or relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••